Shares of Eupraxia Pharmaceuticals Inc. (OTCMKTS:EPRXF – Get Free Report) traded up 3.6% during trading on Wednesday . The stock traded as high as C$8.47 and last traded at C$8.42. 105,192 shares traded hands during mid-day trading, an increase of 1,320% from the average session volume of 7,410 shares. The stock had previously closed at C$8.13.
Eupraxia Pharmaceuticals Stock Performance
The company has a 50-day moving average of C$7.80 and a 200-day moving average of C$6.46.
Eupraxia Pharmaceuticals Company Profile
Eupraxia Pharmaceuticals, Inc (OTCMKTS:EPRXF) is a clinical-stage biotechnology company advancing adeno-associated virus (AAV)-based gene therapies for rare inherited metabolic disorders. The firm’s research platform focuses on developing single-administration treatments designed to address the underlying genetic causes of enzyme deficiencies. Eupraxia’s approach leverages targeted gene delivery to restore or supplement critical metabolic functions in patients with life-threatening conditions.
The company’s lead pipeline candidates include EPRX-101 for Ornithine Transcarbamylase (OTC) deficiency and EPRX-102 for methylmalonic acidemia (MMA), both of which are in preclinical or IND-enabling stages.
Featured Articles
- Five stocks we like better than Eupraxia Pharmaceuticals
- Your Bank Account Is No Longer Safe
- Nvidia CEO Issues Bold Tesla Call
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- This $15 Stock Could Go Down as the #1 Stock of 2026
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
